Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

289 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B, Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H; Austrian Breast And Colorectal Cancer Study Group. Ploner F, et al. Among authors: kubista e. Onkologie. 2003 Apr;26(2):115-9. doi: 10.1159/000069831. Onkologie. 2003. PMID: 12771518 Clinical Trial.
[Effect of hormone receptors on the site of metastases in breast cancer].
Stuller I, Zielinski CC, Aiginger P, Rausch P, Pötzi P, Kubista E, Salzer H, Sevelda P, Langer M, Staffen A, et al. Stuller I, et al. Among authors: kubista e. Onkologie. 1987 Oct;10(5):302-3. doi: 10.1159/000216427. Onkologie. 1987. PMID: 3317171 German. No abstract available.
High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting.
Fuchs EM, Köstler WJ, Horvat R, Hudelist G, Kubista E, Attems J, Zielinski CC, Singer CF. Fuchs EM, et al. Among authors: kubista e. Int J Cancer. 2014 Jul 1;135(1):224-31. doi: 10.1002/ijc.28660. Epub 2014 Jan 28. Int J Cancer. 2014. PMID: 24311197 Free article.
289 results